Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

Given that the PI3K/AKT pathway has manifested its compelling influence on multiple
cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in …

Phosphatidylinositide 3 kinases (PI3Ks) and their downstream mediators AKT and
mammalian target of rapamycin (mTOR) constitute the core components of the …

Abstract Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular
signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is …

Abstract Duvelisib (IPI-145) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K)–δ/γ
isoforms currently in clinical development. PI3K-δ/γ inhibition may directly inhibit malignant T …

PI3Ks regulate several key events in the inflammatory response to damage and infection.
There are four Class I PI3K isoforms (PI3Kα, β, γ, δ), three Class II PI3K isoforms (PI3KC2α …

Over the past two decades, our understanding of phospoinositide 3-kinases (PI3Ks) has
progressed from the identification of an enzymatic activity associated with growth factors …

Phosphoinositides (PIs) make up only a small fraction of cellular phospholipids, yet they
control almost all aspects of a cell's life and death. These lipids gained tremendous research …

Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late-
stage clinical development for hematologic malignancy treatment. This phase 1 study …

Primary immunodeficiencies are inherited disorders of the immune system, often caused by
the mutation of genes required for lymphocyte development and activation. Recently …